Navigation Links
Price Family Foundation funds research collaboration between Albert Einstein College of Medicine and University of Oklahoma
Date:2/4/2014

February 4, 2014 (BRONX, NY) When the foe is a disease-causing microbe, identifying the structure of its component proteins can greatly aid efforts to kill or disable it. Research to gain this knowledge will be bolstered by a $3 million grant from The Price Family Foundation. The gift to Albert Einstein College of Medicine of Yeshiva University and the University of Oklahoma funds a research collaboration to investigate the structural biology of the key proteins of anaerobic microorganisms (those that don't use oxygen).

The research consortium, led at Einstein by Vern Schramm, Ph.D., Steven Almo, Ph.D., and James Love, Ph.D., will focus specifically on Clostridium difficile, a notorious bacterial species that infects the intestinal tract and that the U.S. Centers for Disease Control and Prevention considers an "urgent" health threat.

Toxins produced by C. difficile can damage the lining of the colon, causing colitis. Each year in the U.S., infections with this microbe sicken at least 250,000 people and cause at least 14,000 deaths. The joint project is aimed at finding better treatments for C. difficile infections. It will capitalize on Einstein's expertise in structural biology and its high-throughput analytic capabilities along with OU's expertise in anaerobic microbiology and chemistry.

"Michael Price and his family have a long history of support to Einstein and biomedical research around the country," said Dr. Schramm, professor and chair of biochemistry and Ruth Merns Chair in Biochemistry at Einstein. "This new gift is an inspired way to leverage the unique talents and facilities at our two institutions to make a real advancement in an increasing danger to human health."

"This gift from the Price Family Foundation will put OU researchers in a leading role in this important area of research dealing with the impact of protein," said OU President David L. Boren. "It will further our partnership with Einstein in this area."

A Legacy of Support Mr. Price joined Einstein's Board of Overseers in 2001 and is the former chair of its executive committee. The Price Family Foundation is a generous donor to both Einstein and OU. In 2001, they made what was at the time the largest commitment in Einstein's history: $25 million to help establish the College of Medicine's state-of-the-art center for genetic and translational research. The Michael F. Price Center for Genetic and Translational Medicine/Harold and Muriel Block Research Pavilion officially opened in 2008.

In 2011, the Price Family Foundation made a significant contribution toward consolidating Einstein's Children's Evaluation and Rehabilitation Center's clinical and research units within newly renovated quarters of the Van Etten Building. They have also made a commitment of $2.5 million to help establish the Center for Experimental Therapeutics at Einstein.

The Price Family Foundation is also a long-term supporter of Einstein clinical programs, such as Healthy Steps and the Infant-Parent Court Affiliated Intervention Project, which help young children and their families in underserved communities in the Bronx obtain critical health services.


'/>"/>

Contact: Kim Newman
sciencenews@einstein.yu.edu
718-430-3101
Albert Einstein College of Medicine
Source:Eurekalert

Related biology news :

1. Forests in Central America paying the price of drug trafficking shift
2. Price Family Foundation gift will create groundbreaking structural biology institute
3. Novelty of eco-friendly bamboo garments lures consumers -- if the price is right, Baylor study shows
4. Big brains are pricey, guppy study shows
5. Social bats pay a price with new fungal disease
6. Global prices of pollination-dependent products such as coffee could rise in the long term
7. Climate change may create price volatility in the corn market, say Stanford and Purdue researchers
8. Freeing loggerhead turtles comes at a price
9. Study of rodent family tree puts brakes on commonly held understanding of evolution
10. Crown of Venezuelan paramos: A new species from the daisy family, Coespeletia palustris
11. Population Council to present more than 40 studies at International Conference on Family Planning
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/18/2017)...  Socionext Inc., a global expert in SoC-based imaging and computing ... M820, which features the company,s hybrid codec technology. A demonstration utilizing ... Inc., will be showcased during the upcoming Medtec Japan at Tokyo ... Las Vegas Convention Center April 24-27. ... Click here for an image ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... , ... October 12, 2017 ... ... has launched Rosalind™, the first-ever genomics analysis platform specifically designed for life ... Named in honor of pioneering researcher Rosalind Franklin, who made a major ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... Tbilisi, Georgia (PRWEB) , ... October 11, 2017 , ... ... disaster, taking the lives of over 5.5 million people each year. Especially those living ... the greenovative startup Treepex - based in one of the most pollution-affected countries globally ...
(Date:10/10/2017)... (PRWEB) , ... October 10, ... ... development-stage cancer-focused pharmaceutical company advancing targeted antibody-drug conjugate (ADC) therapeutics, today confirmed ... targeted HPLN (Hybrid Polymerized Liposomal Nanoparticle), a technology developed in collaboration with ...
Breaking Biology Technology: